QQQ   292.99 (+0.94%)
AAPL   143.29 (+0.20%)
MSFT   245.12 (+0.99%)
META   148.10 (+0.71%)
GOOGL   97.65 (+0.73%)
AMZN   103.15 (+2.59%)
TSLA   173.23 (+3.94%)
NVDA   196.14 (+2.36%)
NIO   12.28 (+2.16%)
BABA   111.47 (+0.24%)
AMD   74.29 (+2.54%)
T   20.26 (+0.50%)
MU   60.19 (-2.46%)
F   13.34 (+3.49%)
CGC   2.93 (+3.17%)
GE   80.60 (-0.28%)
DIS   108.24 (+0.60%)
AMC   5.18 (+3.39%)
PFE   43.35 (-0.46%)
PYPL   80.67 (+1.29%)
NFLX   354.04 (+0.26%)
QQQ   292.99 (+0.94%)
AAPL   143.29 (+0.20%)
MSFT   245.12 (+0.99%)
META   148.10 (+0.71%)
GOOGL   97.65 (+0.73%)
AMZN   103.15 (+2.59%)
TSLA   173.23 (+3.94%)
NVDA   196.14 (+2.36%)
NIO   12.28 (+2.16%)
BABA   111.47 (+0.24%)
AMD   74.29 (+2.54%)
T   20.26 (+0.50%)
MU   60.19 (-2.46%)
F   13.34 (+3.49%)
CGC   2.93 (+3.17%)
GE   80.60 (-0.28%)
DIS   108.24 (+0.60%)
AMC   5.18 (+3.39%)
PFE   43.35 (-0.46%)
PYPL   80.67 (+1.29%)
NFLX   354.04 (+0.26%)
QQQ   292.99 (+0.94%)
AAPL   143.29 (+0.20%)
MSFT   245.12 (+0.99%)
META   148.10 (+0.71%)
GOOGL   97.65 (+0.73%)
AMZN   103.15 (+2.59%)
TSLA   173.23 (+3.94%)
NVDA   196.14 (+2.36%)
NIO   12.28 (+2.16%)
BABA   111.47 (+0.24%)
AMD   74.29 (+2.54%)
T   20.26 (+0.50%)
MU   60.19 (-2.46%)
F   13.34 (+3.49%)
CGC   2.93 (+3.17%)
GE   80.60 (-0.28%)
DIS   108.24 (+0.60%)
AMC   5.18 (+3.39%)
PFE   43.35 (-0.46%)
PYPL   80.67 (+1.29%)
NFLX   354.04 (+0.26%)
QQQ   292.99 (+0.94%)
AAPL   143.29 (+0.20%)
MSFT   245.12 (+0.99%)
META   148.10 (+0.71%)
GOOGL   97.65 (+0.73%)
AMZN   103.15 (+2.59%)
TSLA   173.23 (+3.94%)
NVDA   196.14 (+2.36%)
NIO   12.28 (+2.16%)
BABA   111.47 (+0.24%)
AMD   74.29 (+2.54%)
T   20.26 (+0.50%)
MU   60.19 (-2.46%)
F   13.34 (+3.49%)
CGC   2.93 (+3.17%)
GE   80.60 (-0.28%)
DIS   108.24 (+0.60%)
AMC   5.18 (+3.39%)
PFE   43.35 (-0.46%)
PYPL   80.67 (+1.29%)
NFLX   354.04 (+0.26%)
NASDAQ:ARAV

Aravive - ARAV Stock Forecast, Price & News

$1.74
+0.05 (+2.66%)
(As of 01/31/2023 11:12 AM ET)
Add
Compare
Today's Range
$1.68
$1.74
50-Day Range
$1.20
$1.83
52-Week Range
$0.58
$2.40
Volume
15,828 shs
Average Volume
100,551 shs
Market Capitalization
$103.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.25

Aravive MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
385.2% Upside
$8.20 Price Target
Short Interest
Healthy
1.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.27mentions of Aravive in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.99) to ($1.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

155th out of 1,055 stocks

Pharmaceutical Preparations Industry

67th out of 518 stocks


ARAV stock logo

About Aravive (NASDAQ:ARAV) Stock

Aravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

Receive ARAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter.

ARAV Stock News Headlines

Aravive, Inc. (NASDAQ:ARAV) Short Interest Up 23.3% in January
Top Lithium Stock
Today's stock market report features a battery metal lithium stock with great potential.
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
See More Headlines
Receive ARAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter.

ARAV Company Calendar

Last Earnings
11/10/2022
Today
1/31/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARAV
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.20
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+317.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-39,150,000.00
Net Margins
-695.57%
Pretax Margin
-695.57%

Debt

Sales & Book Value

Annual Sales
$7.44 million
Book Value
$2.01 per share

Miscellaneous

Free Float
23,931,000
Market Cap
$103.81 million
Optionable
Optionable
Beta
2.31

Key Executives

  • Gail Frances McIntyreGail Frances McIntyre
    President, Chief Executive Officer & Director
  • Leonard Scott Dove
    Chief Operating Officer
  • Rudy C. Howard
    Chief Financial & Accounting Officer
  • Robert B. Geller
    Chief Medical Officer
  • Amy Franke
    Vice President-Clinical Operations













ARAV Stock - Frequently Asked Questions

Should I buy or sell Aravive stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARAV shares.
View ARAV analyst ratings
or view top-rated stocks.

What is Aravive's stock price forecast for 2023?

5 Wall Street analysts have issued 12 month price targets for Aravive's stock. Their ARAV share price forecasts range from $2.00 to $12.00. On average, they anticipate the company's share price to reach $8.20 in the next twelve months. This suggests a possible upside of 385.2% from the stock's current price.
View analysts price targets for ARAV
or view top-rated stocks among Wall Street analysts.

How have ARAV shares performed in 2023?

Aravive's stock was trading at $1.32 at the beginning of 2023. Since then, ARAV shares have increased by 28.0% and is now trading at $1.69.
View the best growth stocks for 2023 here
.

Are investors shorting Aravive?

Aravive saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,020,000 shares, an increase of 23.3% from the December 31st total of 827,100 shares. Based on an average daily volume of 621,800 shares, the short-interest ratio is presently 1.6 days.
View Aravive's Short Interest
.

When is Aravive's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our ARAV earnings forecast
.

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) posted its quarterly earnings results on Thursday, November, 10th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.13. The firm had revenue of $4.96 million for the quarter, compared to the consensus estimate of $1.24 million. Aravive had a negative net margin of 695.57% and a negative trailing twelve-month return on equity of 190.16%.

What other stocks do shareholders of Aravive own?
What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Who are Aravive's major shareholders?

Aravive's stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amato Giaccia, Gail Frances Mcintyre and Vinay Shah.
View institutional ownership trends
.

How do I buy shares of Aravive?

Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $1.69.

How much money does Aravive make?

Aravive (NASDAQ:ARAV) has a market capitalization of $101.11 million and generates $7.44 million in revenue each year. The company earns $-39,150,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The official website for the company is www.aravive.com. The company can be reached via phone at (936) 355-1910 or via email at christina@sternir.com.

This page (NASDAQ:ARAV) was last updated on 1/31/2023 by MarketBeat.com Staff